Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma
Source abstract
Abstract
Transarterial chemoembolization (TACE) is a first-line treatment for intermediate to advanced-stage liver cancer, with drug-eluting microspheres commonly used as embolic agents. However, currently available drug-eluting microspheres suffer from low drug-loading capacity and limited drug options. In this work, we developed polydopamine-modified polyvinyl alcohol dual-drug-loaded microspheres encapsulating celecoxib and cisplatin (referred to as PCDMS). Physicochemical characterization revealed that the surface of the microspheres displayed increased roughness after polydopamine modification, and celecoxib and cisplatin were successfully loaded onto the microsphere surface. In vitro cell experiments demonstrated that the PCDMS significantly inhibited the proliferation and migration of highly metastatic human liver cancer cells (MHCC-97H) and human liver cancer cells (SMMC-7721). Furthermore, the dual-loaded microspheres exhibited remarkable tumor growth inhibition and reshaped the tumor microenvironment in both subcutaneous H22 liver cancer model in Balb/c mice and intrahepatic VX2 tumor model in New Zealand rabbits, demonstrating a synergistic antitumor effect where 1 + 1>2. This work provides a potential therapeutic approach for the treatment of refractory liver cancer and holds significant translational potential.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Sung · CA A Cancer J. Clin. · 2021 · 71 · 209
2. Llovet · Nat. Rev. Dis. Prim. · 2021 · 7 · 610.1038/s41572-020-00240-3 ↗
3. Anwanwan · Biochim. Biophys. Acta Rev. Canc · 2020 · 1873
4. Liu · Korean J. Radiol. · 2015 · 16 · 12510.3348/kjr.2015.16.1.125 ↗
5. Wáng · Chin. J. Cancer Res. · 2015 · 27 · 96
6. Zhao · Drug Deliv. · 2021 · 28 · 135610.1080/10717544.2021.1943057 ↗
7. Kettenbach · Cardiovasc. Intervent. Radiol. · 2008 · 31 · 46810.1007/s00270-007-9280-6 ↗
8. Welling · J. Clin. Med. · 2023 · 1210.3390/jcm12030918 ↗
9. Zheng · J. Phys. Chem. C · 2015 · 11910.1021/acs.jpcc.5b08558 ↗
10. Liu · Chem. Rev. · 2014 · 114 · 505710.1021/cr400407a ↗
11. Sieghart · J. Hepatol. · 2015 · 62 · 118710.1016/j.jhep.2015.02.010 ↗
12. Mikhail · Expet Opin. Drug Deliv. · 2021 · 18 · 38310.1080/17425247.2021.1835858 ↗
13. Dutta · Pharmacol. Ther. · 2017 · 173 · 10610.1016/j.pharmthera.2017.02.010 ↗
14. Ghosh · Bioorg. Chem. · 2019 · 8810.1016/j.bioorg.2019.102925 ↗
15. Dasari · Eur. J. Pharmacol. · 2014 · 740 · 36410.1016/j.ejphar.2014.07.025 ↗
16. Qi · Chem. Res. Toxicol. · 2019 · 32 · 146910.1021/acs.chemrestox.9b00204 ↗
17. Shahid · Eur. J. Pharmacol. · 2018 · 827 · 4910.1016/j.ejphar.2018.03.009 ↗
18. Cruz · Curr. Med. Chem. · 2022 · 29 · 302810.2174/0929867328666210910125229 ↗
19. Li · Prostag. Other Lipid Mediat. · 2010 · 93 · 11310.1016/j.prostaglandins.2010.08.001 ↗
20. Li · Nan Fang Yi Ke Da Xue Xue Bao · 2009 · 29 · 466
21. Zuo · Ai Zheng · 2006 · 25 · 414
22. Roy · Cancer Chemother. Pharmacol. · 2010 · 65 · 90310.1007/s00280-009-1097-3 ↗
23. Fantappiè · Cancer Res. · 2007 · 67 · 491510.1158/0008-5472.CAN-06-3952 ↗
24. Hennequart · Cancer Immunol. Res. · 2017 · 5 · 69510.1158/2326-6066.CIR-16-0400 ↗
25. Lee · J. Immunother. · 2009 · 32 · 2210.1097/CJI.0b013e31818ac2f7 ↗
26. Nakanishi · Carcinogenesis · 2011 · 32 · 133310.1093/carcin/bgr128 ↗
27. Prima · Proc. Natl. Acad. Sci. U.S.A. · 2017 · 114 · 111710.1073/pnas.1612920114 ↗
28. Li · Biomater. Sci. · 2020 · 8 · 279710.1039/C9BM01775E ↗
29. Zhao · Biomaterials · 2023 · 295
30. Tian · J. Transl. Med. · 2022 · 20 · 46310.1186/s12967-022-03653-8 ↗
31. Zhang · Cancer Lett. · 2018 · 429 · 2910.1016/j.canlet.2018.05.004 ↗
32. Lin · J. Exp. Clin. Cancer Res. · 2018 · 37 · 11310.1186/s13046-018-0727-1 ↗
33. Sullivan · Gut · 2023 · 72 · 32510.1136/gutjnl-2021-325808 ↗
34. Chen · Trends Mol. Med. · 2019 · 25 · 101010.1016/j.molmed.2019.06.007 ↗
35. Taniguchi · Semin. Immunol. · 2014 · 26 · 5410.1016/j.smim.2014.01.001 ↗
36. Propper · Nat. Rev. Clin. Oncol. · 2022 · 19 · 23710.1038/s41571-021-00588-9 ↗
37. Pinato · J Immunother Cancer · 2021 · 910.1136/jitc-2021-003311 ↗
38. Herraez · Oncotarget · 2017 · 810.18632/oncotarget.16119 ↗
39. Plana · Cancer Discov. · 2022 · 12 · 60610.1158/2159-8290.CD-21-0212 ↗
40. Xu · Eur. J. Pharmacol. · 2016 · 776 · 110.1016/j.ejphar.2016.02.035 ↗
41. Kerr · JAMA · 2021 · 325 · 125710.1001/jama.2021.2651 ↗
42. Meyerhardt · JAMA · 2021 · 325 · 127710.1001/jama.2021.2454 ↗
43. Hu · Lancet Gastroenterol Hepatol · 2022 · 7 · 3810.1016/S2468-1253(21)00348-4 ↗
44. Khafaga · Nanomedicine (Lond) · 2021 · 16 · 169110.2217/nnm-2021-0086 ↗